Sonora Investment Management Group LLC Has $10.90 Million Stake in Pfizer Inc. $PFE

Key Points

• Sonora Investment Management Group LLC increased its stake in Pfizer Inc. by 10.6% during Q2, owning 449,853 shares valued at $10.90 million.
• Pfizer reported earnings of $0.78 EPS for the last quarter, surpassing analysts' expectations of $0.58, with revenue reaching $14.65 billion.
• Wall Street analysts have varied opinions on Pfizer's stock, with current ratings showing a consensus of "Hold" and an average target price of $28.12.

Sonora Investment Management Group LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 10.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 449,853 shares of the biopharmaceutical company's stock after buying an additional 43,016 shares during the quarter. Sonora Investment Management Group LLC's holdings in Pfizer were worth $10,904,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after acquiring an additional 2,087 shares during the period. First Hawaiian Bank lifted its stake in shares of Pfizer by 6.9% in the 1st quarter. First Hawaiian Bank now owns 54,455 shares of the biopharmaceutical company's stock valued at $1,380,000 after purchasing an additional 3,531 shares during the period. Versant Capital Management Inc grew its stake in Pfizer by 186.0% during the first quarter. Versant Capital Management Inc now owns 19,446 shares of the biopharmaceutical company's stock worth $493,000 after purchasing an additional 12,647 shares during the period. Finally, Central Pacific Bank Trust Division increased its stake in shares of Pfizer by 19.4% in the 1st quarter. Central Pacific Bank Trust Division now owns 21,634 shares of the biopharmaceutical company's stock valued at $548,000 after acquiring an additional 3,516 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of PFE opened at $23.75 on Friday. The firm has a market cap of $135.03 billion, a PE ratio of 12.63, a PEG ratio of 0.77 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock's fifty day moving average price is $24.55 and its two-hundred day moving average price is $24.13.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on PFE shares. Bank of America boosted their target price on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Morgan Stanley lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a report on Sunday. Finally, Citigroup lifted their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Pfizer has a consensus rating of "Hold" and an average target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.